Blackhawk Capital Partners’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-5,460
Closed -$839K 88
2023
Q1
$839K Buy
5,460
+1,469
+37% +$242K 0.61% 65
2022
Q4
$717K Buy
+3,991
New +$653K 0.56% 67

Other funds holding MRNA

Blackhawk Capital Partners's MRNA Position: Q2 2023 in Review

Blackhawk Capital Partners sold out of Moderna (MRNA) in Q2 2023, closing a stake of 5,460 shares — an estimated $839K sold.

Blackhawk Capital Partners first reported a position in MRNA in Q4 2022 and held it in 2 quarters. The position peaked at $839K in Q1 2023. 965 funds tracked by Wall St. Rank hold MRNA as of Q2 2023.

  • Blackhawk Capital Partners reported no remaining Moderna position as of Q2 2023 after selling out during the quarter.
  • Blackhawk Capital Partners sold 5,460 Moderna shares in Q2 2023, an estimated $839K.
  • Blackhawk Capital Partners first reported a position in Moderna in Q4 2022 and held it in 2 quarters.
  • Blackhawk Capital Partners's Moderna position peaked at $839K in Q1 2023.
  • 965 funds tracked by Wall St. Rank held Moderna as of Q2 2023.

Based on Blackhawk Capital Partners's 13F filing for Q2 2023, filed 18 Jul 2023.